Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway
Authors
Keywords
Cbl-b, PI3K/Akt pathway, Gastric carcinoma, Celecoxib, COX-2, mTOR inhibitor
Journal
TUMOR BIOLOGY
Volume 36, Issue 7, Pages 5607-5615
Publisher
Springer Nature
Online
2015-02-20
DOI
10.1007/s13277-015-3232-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- COX-2-Independent Effects of Celecoxib Sensitize Lymphoma B Cells to TRAIL-Mediated Apoptosis
- (2014) A.-S. Gallouet et al. CLINICAL CANCER RESEARCH
- The Combination of RAD001 and MK-2206 Exerts Synergistic Cytotoxic Effects against PTEN Mutant Gastric Cancer Cells: Involvement of MAPK-Dependent Autophagic, but Not Apoptotic Cell Death Pathway
- (2014) Dongmei Ji et al. PLoS One
- Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
- (2013) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
- (2012) D H Yoon et al. BRITISH JOURNAL OF CANCER
- Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells
- (2012) Shunchao Yan et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells
- (2012) Ying-Xue Wang et al. TUMOR BIOLOGY
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Abrogation of Cbl–PI3K Interaction Increases Bone Formation and Osteoblast Proliferation
- (2011) Tracy Brennan et al. CALCIFIED TISSUE INTERNATIONAL
- Interferon-α sensitizes human gastric cancer cells to TRAIL-induced apoptosis via activation of the c-CBL-dependent MAPK/ERK pathway
- (2011) Jinglei Qu et al. CANCER BIOLOGY & THERAPY
- Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer
- (2011) Taekyu Lim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- mTOR as a therapeutic target in patients with gastric cancer
- (2011) Salah-Eddin Al-Batran et al. INTERNATIONAL JOURNAL OF CANCER
- Mechanisms of mTOR inhibitor resistance in cancer therapy
- (2011) Jennifer S. Carew et al. Targeted Oncology
- Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms
- (2011) B Liu et al. Cell Death & Disease
- mTOR inhibition by everolimus counteracts VEGF induction by sunitinib and improves anti-tumor activity against gastric cancer in vivo
- (2010) Thorsten Fuereder et al. CANCER LETTERS
- Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling
- (2010) Xin He et al. CANCER LETTERS
- Advanced gastric cancer – Slow but steady progress
- (2010) Derek G. Power et al. CANCER TREATMENT REVIEWS
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
- (2009) M. Gupta et al. BLOOD
- Ubiquitin ligase Cbl-b sensitizes leukemia and gastric cancer cells to anthracyclines by activating the mitochondrial pathway and modulating Akt and ERK survival signals
- (2009) Xiujuan Qu et al. FEBS LETTERS
- Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells
- (2009) Ye Zhang et al. JOURNAL OF PATHOLOGY
- Suppression of Tumor Formation by a Cyclooxygenase-2 Inhibitor and a Peroxisome Proliferator-Activated Receptor Agonist in an In vivo Mouse Model of Spontaneous Breast Cancer
- (2008) A. Mustafa et al. CLINICAL CANCER RESEARCH
- Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction
- (2008) Markus Menges et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling
- (2008) Nayoung Kim et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study
- (2008) Likun Chen et al. MEDICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started